Recent studies have shown that broad neutralizing antibody responses are found in about 20% of HIV-1 infected individuals and develop in most cases during the first two to three years following infecfion. In this program, we seek to study the dynamics and mechanism of development of broad neutralizing antibody responses through access to two large and well-characterized primary infection cohorts, Protocol C (donors from sub-Saharan Africa), and the First Choice Program (donors from Southern California). Our focus in this project will be to characterize the neutralizing specificifies as they emerge and evolve in individuals who develop broad and potent serum neutralizafion.
Our specific aims are:
Aim 1. To map the neutralizing specificities in the sera of individuals with broad and potent neutralizing Ab responses. This characterization will allow the selecfion of the most appropriate donors for isolafion of broadly neutralizing human monoclonal Abs (bNmAbs) in Aim 2 and the design of suitable baits for the isolafion of bNmAbs in collaboration with Project 2. A detailed analysis of the specificities responsible for broad serum neutralization will be carried out on the top 5% of neutralizers in the 2 cohorts.
Aim 2. To isolate and characterize bNmAbs from individuals selected in Aim 1. This informafion will be used to trace the evolutionary history of the broadly neutralizing responses in combination with Project 2. We will use the recently successful high-throughput direct functional screening strategy to isolate bNmAbs from four selected individuals from procedures in Aim 1. We will precisely map the epitopes recognized by the bNmABs. This informafion will be used to design
The field of AIDS vaccine is in great need of immunogens and immunizafion strategies able to efficiently induce broadly neutralizing antibodies. This project will use a novel approach to trace the path by which some individuals develop broadly neutralizing responses and thereby gain knowledge for the design of effective vaccines and vaccine strategies.
|Little, Susan J; Kosakovsky Pond, Sergei L; Anderson, Christy M et al. (2014) Using HIV networks to inform real time prevention interventions. PLoS One 9:e98443|
|Hepler, N Lance; Scheffler, Konrad; Weaver, Steven et al. (2014) IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform. PLoS Comput Biol 10:e1003842|
|Gianella, Sara; Massanella, Marta; Richman, Douglas D et al. (2014) Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatment. J Virol 88:7818-27|
|Wagner, Gabriel A; Pacold, Mary E; Kosakovsky Pond, Sergei L et al. (2014) Incidence and prevalence of intrasubtype HIV-1 dual infection in at-risk men in the United States. J Infect Dis 209:1032-8|
|Chaillon, A; Gianella, S; Massanella Luna, M et al. (2014) A case cluster demonstrating the relationship between HLA concordance and virologic and disease outcomes in human immunodeficiency virus infection. Virology 449:104-8|
|Crotty, Shane (2014) T follicular helper cell differentiation, function, and roles in disease. Immunity 41:529-42|
|Ogunniyi, Adebola O; Thomas, Brittany A; Politano, Timothy J et al. (2014) Profiling human antibody responses by integrated single-cell analysis. Vaccine 32:2866-73|
|Sok, Devin; Doores, Katie J; Briney, Bryan et al. (2014) Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med 6:236ra63|
|King, Helen L; Keller, Samuel B; Giancola, Michael A et al. (2014) Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav 18:1722-5|
|Choi, Youn Soo; Eto, Danelle; Yang, Jessica A et al. (2013) Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J Immunol 190:3049-53|
Showing the most recent 10 out of 21 publications